Climb Bio (CLYM) Other Operating Expenses (2020 - 2024)
Climb Bio's (CLYM) quarterly Other Operating Expenses came in at $2.8 million in Q3 2024, up 120.86% YoY from $1.3 million in Q4 2023, and up 87.54% on a QoQ basis from $1.5 million in Q2 2024.
Climb Bio (CLYM) Other Operating Expenses (2020 - 2024) Analysis & Trends
Climb Bio (CLYM) has 5 years of Other Operating Expenses data on file, last reported at $2.8 million in Q3 2024.
- Quarterly Other Operating Expenses rose 120.86% year-over-year to $2.8 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $2.8 million (up 1.42% YoY) and the FY2024 annual result came in at $51.7 million, changed N/A from the prior year.
- Other Operating Expenses improved to $2.8 million in Q3 2024, from $1.5 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $9.4 million in Q4 2020 to a low of $20000.0 in Q3 2021.
- A 5-year average of $1.6 million and a median of $900000.0 in 2023 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2021 — Other Operating Expenses tumbled 99.36% — and 2023, when it jumped 958.82%.
- Tracing CLYM's Other Operating Expenses over 5 years: stood at $9.4 million in 2020, then plunged by 99.36% to $60000.0 in 2021, then surged by 41.67% to $85000.0 in 2022, then soared by 1383.53% to $1.3 million in 2023, then jumped by 120.86% to $2.8 million in 2024.
- The last three Other Operating Expenses figures came in at $2.8 million (Q3 2024), $1.5 million (Q2 2024), and $1.3 million (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2.79 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 1.11 Mn |
| Mar 31, 2023 | 900,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Dec 31, 2021 | 60,000.00 |
| Sep 30, 2021 | 20,000.00 |
| Jun 30, 2021 | 315,000.00 |
| Dec 31, 2020 | 9.45 Mn |
| Jun 30, 2020 | 35,000.00 |